Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

ulation, entry criteria and study conduct. OncoGenex plans to

revise and submit the protocol to FDA for a Special Protocol

Assessment prior to initiating the registration trial.

- OncoGenex completed patient enrollment in its Phase 1 clinical trial

evaluating the safety of SN2310 in patients with advanced cancer.

Conference Call on Monday, November 10, 2008 at 4:30 p.m. Eastern Time

OncoGenex management will host a conference call on Monday, November 10, 2008, at 4:30 p.m. Eastern Time to provide a business and product update and discuss the third quarter results. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7903 (U.S. & Canada) or 719-325-4917 (International). A webcast replay will be available approximately two hours after the call and will be archived on http://www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... compound found in plants and food groups, notably red ... mitochondria, the cell,s energy supplier. "The results were ... at Harvard Medical School and the study,s senior author. ... The findings are to be published May ...
...  The Diagnostic Marketing Association ( DxMA ), serving marketing, ... device market segments, today presented its 2011 Marketer of ... ), a leading molecular diagnostics company. Presented at the ... recognizes innovation by marketers seeking to highlight their company ...
... SAN DIEGO, May 1, 2012 AnaptysBio, Inc., ... antibody discovery partnership with Gilead Sciences, Inc. to ... http://photos.prnewswire.com/prnh/20111205/SF16052LOGO ) Under this ... SHM-XEL platform will be transferred to Gilead for ...
Cached Biology Technology:More evidence for longevity pathway 2Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year 2AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences 2
(Date:4/17/2014)... COLUMBIA, Mo. April 17 In the most densely ... States, forests reflect two centuries of human needs, values ... logging and clearing forests for agriculture and development, have ... today, a U.S. Forest Service study reports. , The ... forest conditions and management needs in the Northern United ...
(Date:4/17/2014)... there was a word for chili peppers. Information about ... with a study of the appearance of words for ... where jalapeos were domesticated and highlight the value of ... Kraft et al.) of nine papers presented in a ... National Academy of Sciences on plant and animal ...
(Date:4/17/2014)... new modeling study suggests that fish consumption advisories ... exposure to long-lived contaminants like persistent organic pollutants ... team of researchers including University of Toronto Scarborough ... looks at how different levels of environmental contamination, ... of chemicals in the body influenced exposure in ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Chickens to chili peppers 2Chickens to chili peppers 3Fish consumption advisories fail to cover all types of contaminants 2
... piece to the mounting body of evidence that suggests ... "passive ventilation" significantly increases survival rates, compared to the ... an online edition of Annals of Emergency Medicine, compared ... arrest outside a hospital setting and were resuscitated in ...
... University of Jerusalem have succeeded for the first time ... basic cellular mechanism that enables networks of neurons to ... research may lead to the upgrading of computer algorithms ... as to the development of innovative treatments for auditory ...
... August 11, 2009 Researchers at the Department of ... the effects of formal education on the symptoms of ... diminishes the impact of Alzheimer,s disease on cognition even ... The results are published in the current issue of ...
Cached Biology News:Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Hebrew U. researchers shed light on the brain mechanism responsible for processing of speech 2Formal education lessens the impact of Alzheimer's disease 2
... Oncostatin M (OSM) is a pleiotropic cytokine ... Kaposis sarcoma cells. OSM inhibits the growth ... simulates fibroblast, smooth muscle and Kaposis sarcoma ... and low density lipoprotein receptor expression on ...
Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
... 15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ... is the latanoprost-related isomer containing both ... an inverted (β) hydroxyl group at ... PGF2α isopropyl ester is a potential ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
Biology Products: